Ionis Pharmaceuticals, Inc. (IONS) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 874.09M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 16.02M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $874.09M | $16.02M | (m) |
| 2026-03-31 | (m) | $1.06B | $17.43M | (m) |
| 2025-12-31 | (m) | $943.71M | $15.91M | (m) |
| 2025-09-30 | (m) | $966.96M | $11.78M | (m) |
| 2025-06-30 | (m) | $944.05M | $10.52M | (m) |
| 2025-03-31 | (m) | $717.25M | $10.53M | (m) |
| 2024-12-31 | (m) | $705.14M | $11.21M | (m) |
| 2024-09-30 | (m) | $803.07M | $10.45M | (m) |
| 2024-06-30 | (m) | $813.46M | $11.57M | (m) |
| 2024-03-31 | (m) | $776.62M | $9.94M | (m) |
| 2023-12-31 | (m) | $787.65M | $9.13M | (m) |
| 2023-09-30 | (m) | $615.03M | $9.76M | (m) |
| 2023-06-30 | (m) | $630.59M | $9.08M | (m) |
| 2023-03-31 | (m) | $575.97M | $11.29M | (m) |
| 2022-12-31 | (m) | $587.37M | $14.12M | (m) |
| 2022-09-30 | (m) | $875.48M | $12.66M | (m) |
| 2022-06-30 | (m) | $848.81M | $14.22M | (m) |
| 2022-03-31 | (m) | $840.77M | $12.43M | (m) |
| 2021-12-31 | (m) | $810.46M | $10.84M | (m) |
| 2021-09-30 | (m) | $660.73M | $11.92M | (m) |
| 2021-06-30 | (m) | $687.72M | $11.92M | (m) |
| 2021-03-31 | (m) | $707.50M | $11.98M | (m) |
| 2020-12-31 | (m) | $729.26M | $11.95M | (m) |
| 2020-09-30 | (m) | $932.66M | $9.66M | (m) |
| 2020-06-30 | (m) | $940.48M | $7.54M | (m) |
| 2020-03-31 | (m) | $958.75M | $5.89M | (m) |
| 2019-12-31 | (m) | $1.12B | $4.38M | (m) |
| 2019-09-30 | (m) | $821.03M | $5.19M | (m) |
| 2019-06-30 | (m) | $798.53M | $4.23M | (m) |
| 2019-03-31 | (m) | $752.47M | $2.86M | (m) |
| 2018-12-31 | (m) | $599.67M | $1.82M | (m) |
| 2018-09-30 | (m) | $568.84M | (m) | (m) |
| 2018-06-30 | (m) | $541.76M | (m) | (m) |
| 2018-03-31 | (m) | $536.28M | (m) | (m) |
| 2017-12-31 | (m) | $507.67M | (m) | (m) |
| 2017-09-30 | (m) | $495.71M | (m) | (m) |
| 2017-06-30 | (m) | $485.73M | (m) | (m) |
| 2017-03-31 | (m) | $420.05M | (m) | (m) |
| 2016-12-31 | (m) | $346.62M | (m) | (m) |
| 2016-09-30 | (m) | $237.84M | (m) | (m) |
| 2016-06-30 | (m) | $176.04M | (m) | (m) |
| 2016-03-31 | (m) | $257.99M | (m) | (m) |
| 2015-12-31 | (m) | $283.70M | (m) | (m) |
| 2015-09-30 | (m) | $316.99M | (m) | (m) |
| 2015-06-30 | (m) | $311.94M | (m) | (m) |
| 2015-05-31 | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $248.58M | (m) | (m) |
| 2014-12-31 | (m) | $214.16M | (m) | (m) |
| 2014-09-30 | (m) | $171.55M | (m) | (m) |
| 2014-06-30 | (m) | $151.07M | (m) | (m) |
| 2014-03-31 | (m) | $132.09M | (m) | (m) |
| 2013-12-31 | (m) | $147.28M | (m) | (m) |
| 2013-09-30 | (m) | $124.91M | (m) | (m) |
| 2013-06-30 | (m) | $112.92M | (m) | (m) |
| 2013-03-31 | (m) | $122.17M | (m) | (m) |
| 2012-12-31 | (m) | $102.05M | (m) | (m) |
| 2012-09-30 | (m) | $114.58M | (m) | (m) |
| 2012-06-30 | (m) | $123.69M | (m) | (m) |
| 2012-03-31 | (m) | $101.17M | (m) | (m) |
| 2011-12-31 | (m) | $99.09M | (m) | (m) |
| 2011-09-30 | (m) | $93.10M | (m) | (m) |
| 2011-06-30 | (m) | $101.01M | (m) | (m) |
| 2011-03-31 | (m) | $99.69M | (m) | (m) |
| 2010-12-31 | (m) | $108.47M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $121.60M | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $107.19M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |